



This is a repository copy of *PWE-145 The role of a gluten free diet in 'lifestylers'? the first double blind randomised study.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/134933/>

Version: Accepted Version

Proceedings Paper:

Rej, A., Kurien, M. orcid.org/0000-0002-4227-9500, Tosi, P. et al. (2 more authors) (2018) PWE-145 The role of a gluten free diet in 'lifestylers'? the first double blind randomised study. In: Gut. .

<https://doi.org/10.1136/gutjnl-2018-BSGAbstracts.439>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

The role of a gluten free diet in 'lifestylers'? The first double blind randomized study

Rej A¹, Kurien M¹, Trott N¹, Sanders D S¹

¹Academic Unit of Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, S10 2JF

Introduction: A gluten free diet (GFD) is essential in the management of coeliac disease, as well as several studies demonstrating its utility as a dietary therapy in patients with irritable bowel syndrome. The aim of this double-blind placebo controlled study was to assess the role of a GFD in a healthy population who take a GFD as a lifestyle choice ('lifestylers').

Methods: Subjects were recruited via an advert, following exclusion criteria including coeliac disease. Following selection, subjects were commenced on a 2 week GFD following evaluation by a dietitian. Participants were then randomized to receive either organic gluten (Group A, Vital Gluten 14g gluten protein/day) or gluten free flour (Group B) in pre-made bags, over a 2 week period. These were sprinkled on their food twice daily. Gastrointestinal Symptom Rating Scale (GSRS) scores were assessed at baseline (following 2 weeks GFD) and after 2 weeks of randomization. Data was analyzed using SPSS version 22.

Results: 45 subjects were identified with 28 participants recruited into the trial (Group A; n=14, Group B; n=14) following exclusion criteria. Median age was 36.5 years (range: 19-63) and 21 (75%) were female. There was no significant difference in baseline demographics between both groups (p=0.54). Over a 2 week period there was no significant difference in gastrointestinal symptoms or fatigue in either group, as seen in Table 1.

GSRS	Group A (Baseline)	Group A (End of Intervention)	Difference from Baseline (Paired T-test), p-value	Group B (Baseline)	Group B (End of Intervention)	Difference from Baseline (Paired T-test), p-value
Abdo Pain	2.50 +/- 1.40	2.14 +/- 1.70	0.504	2.35 +/- 1.33	2.07 +/- 0.99	0.486
Reflux	1.71 +/- 1.13	1.64 +/- 1.15	0.72	2.50 +/- 2.20	2.57 +/- 1.95	0.895
Indigestion	2.14 +/- 1.35	2.07 +/- 1.32	0.876	2.14 +/- 1.35	1.79 +/- 0.97	0.336
Diarrhoea	2.71 +/- 1.93	1.64 +/- 0.92	0.03	1.85 +/- 1.46	1.86 +/- 1.35	1
Constipation	2.50 +/- 1.82	2.46 +/- 1.81	0.697	1.92 +/- 1.54	2.50 +/- 1.65	0.179
Fatigue Score	6.61 +/- 2.36	6.00 +/- 2.98	0.585	6.57 +/- 2.44	5.36 +/- 2.27	0.232

Conclusion: This study demonstrates that gluten is unlikely to be the culprit agent for gastrointestinal symptoms or fatigue in healthy individuals. A GFD has no evidence base in individuals who do not have coeliac disease or IBS. The public should be discouraged from considering a GFD of their own volition.